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lung cancer (NSCLC). Methods: A Markov Model was developed to evaluate the 
disease progression of a cohort of patients with ALK +ve advanced NSCLC in a three 
year period, that will be treated with Crizotinib. The model compares scenarios With 
and Without Crizotinib. The difference in total costs is the net impact of Crizotinib 
on the health care budget. Local epidemiologic data was used. Costs were estimated 
from Panama Public Health System ($US, 2012) and included costs of treatment, 
administration and monitoring, palliative care, and severe adverse events. The base 
case scenario assumes 100% testing rate for ALK in incident patients and 100% 
market share for crizotinib in ALK+Ve advanced NSCLC patients. Sensitivity analy-
ses were performed for 80-100% market share [3] Results: In a three year period, 
23 patients received Crizotinib (from a cohort of 609 advanced NSCLC patients). 
Cost related to drug acquisition and management of adverse in a world “With” and 
“Without” Crizotinib during three years are $13.426.918 and $12.670.537 respec-
tively which represents $756.381 of budget impact associated with the insertion of 
Crizotinib in the market, however it shows savings in terms of drug administration, 
monitoring costs and progression cost, with an estimated of $471.952 (Difference 
between the two scenarios of $3.931.399 and $4.403.351). Net budget Impact for the 
three year period is $284.428, which represents for the first year ($48.997, $0.0018 
per patient-per month [PMPM]) approximately 0.00289% of Panama’s Total Public 
Health Expenditure (2011). [4] If the Crizotinib market share is assumed to be 80%, 
the net impact was $92.996. ConClusions: Crizotinib for the treatment of ALK+ 
NSCLC patients has a minimal incremental budget impact on the overall expendi-
ture within the Panama Health System.
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objeCtives: Newly diagnosed glioblastoma multiforme (GBM) is associated with 
poor prognosis and limited treatment options. The placebo controlled AVAglio 
study demonstrated that the addition of bevacizumab to radiotherapy (RT) plus 
temozolomide (TMZ) improves progression-free survival (PFS) by 4.4 months, and 
maintains health-related quality of life in patients with newly diagnosed GBM. A 
budget impact model (BIM) has been developed to calculate the costs associated 
with the introduction of bevacizumab for the treatment of newly diagnosed GBM in 
the UK. Methods: The BIM is based on UK epidemiological and resource data and 
compares a base case in which all eligible patients are treated with radiotherapy + 
TMZ only with a scenario in which bevacizumab is introduced with increased uptake 
over a three year period. The model combines drug, adverse events, and administra-
tive costs to estimate the total cost of treating the eligible patient population in the 
UK using published sources converted into £ (2013). Results: The BIM estimates 
that, in year 1, with an expected 10% uptake of bevacizumab, the total cost would be 
£5,619,457, £11,463,690 in year 2, with an expected uptake of 20%, and £16,688,655 
in year 3, with an expected uptake of 30%. When these costs are considered in the 
context of the total oncology costs for the UK in 2013, the budget impact of the intro-
duction of bevacizumab in years 1, 2 and 3 is 0.08 %, 0.17% and 0.25%, respectively. 
When the costs related to bevacizumab alone are considered in the context of the 
total oncology drug budget for the UK in 2013, the costs for bevacizumab for years 
1, 2 and 3 are 0.42%, 0.95 % and 1.43% of the budget, respectively. ConClusions: 
The introduction of bevacizumab for the treatment of newly diagnosed GBM in the 
UK is associated with a low budget impact.
PCN46
Budget ImPACt ANAlysIs of BevACIzumAB Plus ChemotherAPy versus 
BevACIzumAB ANd ANtI-egfr wIth ChemotherAPy for fIrst ANd 
seCoNd lINe treAtmeNt of metAstAtIC ColoreCtAl CANCer IN russIAN 
federAtIoN
Yagudina R., Kulikov A., Komarov I.
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To estimate the budget impact of bevacizumab plus chemotherapy 
for first and second line metastatic colorectal cancer (mCRC) treatment compared 
with chemotherapy with anti-EGFR for first line and bevacizumab plus chemo-
therapy for second line according to the Russian health care system. Methods: 
The budget impact analysis was conducted. Direct expenses associated with mCRC 
and resulting follow-up costs were calculated using general tariff agreement of 
Russian statutory health insurance and official national statistics (accepted 
exchange rate was 1 $ = 30 RUB). Results: Bevacizumab plus chemotherapy 
for first and second line in the mCRC therapy provided cost saving benefits com-
pared with chemotherapy with anti-EGFR for first line and bevacizumab plus 
chemotherapy for second line. Total health care costs of mCRC therapy were 
approximately 1 145 826 RUB (38 194 $) in bevacizumab+FOLFOX 1 line therapy, 
544 905 RUB (18 164 $) in bevacizumab+FOLFIRI 2 line therapy and 2 957 187 RUB 
(98 573 $) in panitumumab+FOLFOX4 1 line therapy, 872 226 RUB (29 074 $) in 
bevacizumab+FOLFOX4 2 line therapy. Treatment of mCRC using bevacizumab 
treatment combinations compared to chemotherapy with anti-EGFR leads to cost 
savings of 2 138 681 RUB (71 289 $). ConClusions: The results of budget impact 
analysis illustrate that bevacizumab treatment combinations in the mCRC treat-
ment in comparison with chemotherapy with anti-EGFR has potential to reduce 
Russian health care system total costs for mCRC treatment.
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objeCtives: To estimate the burden of disease and costs associated with smok-
ing in Colombia. Methods: Epidemiological data was retrieved from the National 
Administrative Department of Statistics (DANE), Integrated Information System 
on Social Protection (SISPRO) and National Survey of Substance abuse 2008 data-
bases. Costs are expressed in 2012 prices and were obtained from local studies and 
regional approximations. A micro-simulation first order Monte Carlo model was 
constructed, incorporating natural history, costs and quality of life of the most 
important diseases related with smoking: stroke, Coronary Heart Disease (CHD), 
Chronic Obstructive Pulmonary Disease (COPD), and lung cancer. The model was 
programmed in Excel (Microsoft Excel ® Office Professional Edition 2003) with Visual 
Basic ® Macros (Microsoft Visual Basic® 6.3). A software package was installed to 
improve the random number generator function in Excel®. Results: 15.9% of the 
total annual deaths in Colombia are attributable to smoking (6,776 heart disease, 
6,619 COPD, 3,544 lung cancer and 1,831 stroke). Smoking is responsible for 112,891 
hospital admission and it is estimated that 10,606 people are diagnosed annually 
with cancer caused by smoking. The direct health care costs associated with smok-
ing is USD$ 1.692 million dollars (USD$863,103,308 heart diseases, USD$442,619,734 
COPD, USD$ 170,000,285 lung cancer and USD$216,852,028 stroke). ConClusions: 
Smoking is directly responsible for the loss of 674.262 lives each year in Colombia 
and generates an annual direct health care cost of more than 4 billion Colombian 
pesos, equivalent to 0.6% of Colombian GDP and 10.5% of health care spending. 
These results could be useful for decision makers to reinforce public policies regard-
ing smoking cessation in Colombia.
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objeCtives: To estimate the budget impact of bevacizumab combinations in the 
metastatic colorectal cancer (mCRC) treatment and chemotherapy with anti-EGFR 
for first and second line according to the Russian health care system. Methods: 
The budget impact analysis was conducted. Direct expenses associated with 
mCRC and resulting follow-up costs were calculated using general tariff agree-
ment of Russian statutory health insurance and official national statistics (accepted 
exchange rate was 1 $ = 30 RUB). Results: Bevacizumab treatment combinations 
in the mCRC therapy provided cost saving benefits compared with chemotherapy 
with anti-EGFR for first and second line therapy. Total health care costs of mCRC 
therapy were approximately 1 187 115 RUB (39 571 $) in bevacizumab+FOLFIRI 1 
line therapy, 662 242 RUB (22 075 $) in bevacizumab+CAPOX 2 line therapy and 2 
518 311 RUB (83 944 $) in cetuximab+FOLFIRI 1 line therapy, 872 226 RUB (29 074 $) 
in bevacizumab+FOLFOX4 2 line therapy. Treatment of mCRC using bevacizumab 
treatment combinations compared to chemotherapy with anti-EGFR leads to cost 
savings of 1 541 181 RUB (51 373 $). ConClusions: The results of budget impact 
analysis illustrate that bevacizumab treatment combinations in the mCRC treat-
ment in comparison with chemotherapy with anti-EGFR has potential to reduce 
Russian health care system total costs for mCRC treatment.
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objeCtives: To analyze the budget impact of the use of nilotinib in first and second 
line chronic myeloid leukemia (CML), compared with imatinib and dasatinib, from 
the perspective of a third party payer in Colombia. Methods: A Markov model 
was developed with a 5-year time horizon simulating first and second line treat-
ment of CML patients, with treatment options including nilotinib, imatinib and 
dasatinib. 2013 incidence and prevalence figures were estimated from international 
data. Base case market share for each compound was obtained from public national 
medicines registry (Sismed) for the years 2012 – 2013. Resource utilization and costs 
of medicines, health care services and adverse events were estimated according to 
clinical trials data and local health care provider databases. The analysis estimated 
up to 80% market share for nilotinib in both lines. A univariate sensitivity analy-
sis was developed to identify the effect of individual parameter variation on final 
results. Results: Nilotinib inclusion as a first and second line treatment option 
for CML patients resulted in a cumulative impact of COP $14.961 million over 5 
years, corresponding to a 0.056% per capita premium (UPC) in the Colombian care 
health system. Year to year, the impact was calculated from COP $1,168 million to 
COP $6,588 million on the fifth year. The sensitivity analysis showed the costs of 
technologies, health care services and disease progression as the most relevant 
variables. ConClusions: The budget impact analysis showed that increasing the 
use of nilotinib both in first and second line treatment of CML patients poses a 
minimal impact on the Colombian health care system, within parameters similar 
to those used in 2012 for the inclusion of technologies in the benefit plan. Additional 
benefits in lower progression rates and potential increased survival may favor this 
technology to be reimbursed within the premium (UPC) in Colombia.
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objeCtives: The purpose of this model is to examine the budgetary impact of the 
decision to reimburse crizotinib for patients with ALK+ve advanced non-small-cell 
